Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq of KMT2D Knockout and KMT2D WT melanoma in mice

ABSTRACT: RNA-seq of KMT2D Knockout and KMT2D WT melanoma in mice

PROVIDER: PRJNA480453 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7504790_1.fastq.gz	Fastqsanger.gz
	SRR7504790_2.fastq.gz	Fastqsanger.gz
	SRR7504791_1.fastq.gz	Fastqsanger.gz
	SRR7504791_2.fastq.gz	Fastqsanger.gz
	SRR7504792_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Genome-wide maps of chromatin state in KMT2D Knockout and KMT2D WT melanoma in mice

Project description:Genome-wide maps of chromatin state in KMT2D Knockout and KMT2D WT melanoma in mice

| PRJNA480444 | ENA

RNA-seq of KMT2D Knockout and KMT2D WT melanoma in mice

Project description:Somatic mutations in various epigenetic regulators, including histone methyltransferases KMT2C and KMT2D, have emerged as important cancer-driving events. However, the mechanism of action and therapeutic vulnerability imparted by these mutations remain poorly understood. We identified KMT2D and 8 other epigenetic regulators as potential suppressors to melanoma initiation through an in vivo pooled epigenome-focused RNAi screen. Loss of KMT2D, which exhibits somatic mutations in human melanoma and other cancers, drastically enhanced melanoma progression in xenograft models and a BRAFV600E-driven genetically engineered mouse model of melanoma. Epigenome profiling of 6 histone marks and chromatin state alterations showed substantial reprogramming of H3K4me1- and H3K27ac-marked active enhancer states in KMT2D mutant tumors. Energy metabolic pathways such as glycolysis, OxPhos and TCA/electron transport showed high degree of deregulation which was confirmed with metabolic profiling. Pharmacological abrogation of glycolysis led to reduced proliferation and tumorigenesis preferentially in KMT2D mutant cells. Mechanistically, we find that enhancer loss at IGFBPs increases IGF signaling and downstream AKT phosphorylation that leads to upregulation of metabolic pathways rendering KMT2D mutant cells dependent on these energy metabolism pathways for their higher growth potential. Overall, we present evidence that KMT2D mutations promote tumorigenesis by reprogramming energy metabolism pathways through enhancer reprogramming.

2020-11-16 | GSE116852 | GEO

Genome-wide maps of chromatin state in KMT2D Knockout and KMT2D WT melanoma in mice

2020-11-16 | GSE116851 | GEO

Single cell gene expression of virus-specific WT amd KMT2D-deficient CD4+ T-cells

Project description:To understand how KMT2D impacts anti-viral CD4 T-cell responses, we performed scRNA-seq on WT and KMT2D-/- effector CD4 T-cells obtained from LCMV Armstrong infected mice

2025-05-09 | GSE282033 | GEO

RNA-Seq of ADAMTS4 knockout mice and WT mice

Project description:RNA-Seq of ADAMTS4 knockout mice and WT mice

| PRJNA1368492 | ENA

ChIP-seq and RNA-seq analysis of KMT2D-silenced metastatic melanoma cells

Project description:Purpose: Study of the mechanism trough which KTM2D regulates chromatin modification and transcription in a xenograft model of human metatstatic melanoma Methods: We generated patient derived xenografts (PDXs) from metastatic melanoma (MM) biopsies of three different patients. The MMs carry NRASQ61L, NRASQ61Q or BRAFV600 mutations. Cells from secondary PDX (PDX2) were transduced with lentiviral vectors carrying Luciferase (shLuc) and KMT2D (shKMT2D) hairpins and mRNA profiles and genome-wide chromatin-state maps were generated by deep sequencing using Illumina HiSeq2000. Results: we found that KMT2D regulates the activity of a subset of enhancers required for expression of specific genes.

2016-04-21 | GSE71854 | GEO

Examine the epigenetic consequences of KMT2D loss in melanoma using ChIP-seq profiling

Project description:Cellular plasticity contributes to melanoma progression and resistance to treatment, but the epigenetic mechanisms driving these changes are not well understood. In a Braf-mutant mouse model, we show that loss of Kmt2d, an enzyme that adds H3K4me1 to enhancers, speeds up melanoma development and shifts cells toward a neural crest-like state. Using single-cell multiome analysis, we found that this shift is driven by increased activity of TFAP2 transcription factors, linked to changes at enhancer regions. Kmt2d loss also leads to a more immunosuppressive tumor environment, with higher levels of suppressive immune cells. This study provides the first genetic evidence that enhancer disruption plays a key role in cell identity changes in melanoma.

2026-07-04 | GSE302057 | GEO

RNA-Seq of ADAMTS4 knockout mice and WT mice

Project description:RNA-Seq was performed on ADAMTS4 knockout mice and WT mice after 7 days of DSS treatment.

2025-11-28 | GSE311026 | GEO

The KMT2D Kabuki syndrome histone methylase controls neural crest cell differentiation and facial morphology

Project description:We report RNA-seq from mouse E14.25 WT and KMT2D neural crest cell knockout palatal shelves

2020-06-01 | GSE149688 | GEO

Examine the epigenetic consequences of KMT2D loss in melanoma using ChIP-seq profiling [CUT&Run]

2026-07-04 | GSE301779 | GEO